Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue
November 8, 2022 4:04 PM ESTCoherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.96), $0.22 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $45.4 million versus the consensus estimate of $57.27 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
... More